These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 34001809)

  • 21. Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study.
    Itoh H; Komuro I; Takeuchi M; Akasaka T; Daida H; Egashira Y; Fujita H; Higaki J; Hirata KI; Ishibashi S; Isshiki T; Ito S; Kashiwagi A; Kato S; Kitagawa K; Kitakaze M; Kitazono T; Kurabayashi M; Miyauchi K; Murakami T; Murohara T; Node K; Ogawa S; Saito Y; Seino Y; Shigeeda T; Shindo S; Sugawara M; Sugiyama S; Terauchi Y; Tsutsui H; Ueshima K; Utsunomiya K; Yamagishi M; Yamazaki T; Yo S; Yokote K; Yoshida K; Yoshimura M; Yoshimura N; Nakao K; Nagai R;
    Diabetes Obes Metab; 2019 Apr; 21(4):791-800. PubMed ID: 30393955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale and Design of the Standard Versus Intensive Statin Therapy for Hypercholesterolemic Patients with Diabetic Retinopathy (EMPATHY) Study: a Randomized Controlled Trial.
    Ueshima K; Itoh H; Kanazawa N; Komuro I; Nagai R; Takeuchi M; Yamazaki T;
    J Atheroscler Thromb; 2016 Aug; 23(8):976-90. PubMed ID: 26961114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
    Ferdinand KC
    J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Insights into the Role of Visit-to-Visit Glycemic Variability and Blood Pressure Variability in Cardiovascular Disease Risk.
    Zhou JJ; Nuyujukian DS; Reaven PD
    Curr Cardiol Rep; 2021 Mar; 23(4):25. PubMed ID: 33655430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensive versus standard blood pressure treatment improves cardiovascular outcomes without any difference in patient-reported outcomes.
    McCartney D; McManus RJ
    BMJ Evid Based Med; 2018 Jun; 23(3):114-115. PubMed ID: 29789320
    [No Abstract]   [Full Text] [Related]  

  • 28. Effectiveness of statin intensive therapy in type 2 diabetes mellitus with high visit-to-visit blood pressure variability.
    Ikeda S; Shinohara K; Enzan N; Matsushima S; Tohyama T; Funakoshi K; Kishimoto J; Itoh H; Komuro I; Tsutsui H
    J Hypertens; 2021 Jul; 39(7):1435-1443. PubMed ID: 34001809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensive statin therapy for Indians: Part-I. Benefits.
    Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
    Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.